MA55910A - Immunothérapies ciblant cd123 - Google Patents

Immunothérapies ciblant cd123

Info

Publication number
MA55910A
MA55910A MA055910A MA55910A MA55910A MA 55910 A MA55910 A MA 55910A MA 055910 A MA055910 A MA 055910A MA 55910 A MA55910 A MA 55910A MA 55910 A MA55910 A MA 55910A
Authority
MA
Morocco
Prior art keywords
immunotherapies targeting
immunotherapies
targeting
Prior art date
Application number
MA055910A
Other languages
English (en)
Inventor
William Crago
Brendan P Eckelman
Andrew Hollands
Jordan Jarjour
Kyle Jones
Wai-Hang Leung
Milton Ma
Chelsie Macedo
Mark Pogson
John C Timmer
Original Assignee
2Seventy Bio Inc
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 2Seventy Bio Inc, Inhibrx Inc filed Critical 2Seventy Bio Inc
Publication of MA55910A publication Critical patent/MA55910A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
MA055910A 2019-05-08 2020-05-07 Immunothérapies ciblant cd123 MA55910A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962845307P 2019-05-08 2019-05-08

Publications (1)

Publication Number Publication Date
MA55910A true MA55910A (fr) 2022-03-16

Family

ID=73051377

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055910A MA55910A (fr) 2019-05-08 2020-05-07 Immunothérapies ciblant cd123

Country Status (8)

Country Link
US (1) US20220315638A1 (fr)
EP (1) EP3966338A1 (fr)
JP (1) JP2022531718A (fr)
CN (1) CN114402079A (fr)
AU (1) AU2020267559A1 (fr)
CA (1) CA3139512A1 (fr)
MA (1) MA55910A (fr)
WO (1) WO2020227481A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123938A1 (fr) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Complexes d'immunorécepteurs régulés par un agent de dimérisation
KR20220004751A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
WO2020227475A1 (fr) 2019-05-08 2020-11-12 Bluebird Bio, Inc. Immunothérapies ciblant cll -1
WO2023230512A1 (fr) 2022-05-26 2023-11-30 2Seventy Bio, Inc. Compositions pour conserver des vecteurs lentiviraux et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3027204B1 (fr) * 2013-07-29 2022-01-05 2seventy bio, Inc. Protéines de signalisation multipartites et leurs utilisations
JP6894430B2 (ja) * 2015-08-24 2021-06-30 セレクティスCellectis 統合された制御機能を有するキメラ抗原受容体
PT3383425T (pt) * 2015-12-04 2020-10-07 Boehringer Ingelheim Int Polipéptidos biparatópicos que antagonizam a sinalização wnt em células tumorais

Also Published As

Publication number Publication date
US20220315638A1 (en) 2022-10-06
AU2020267559A1 (en) 2022-01-06
JP2022531718A (ja) 2022-07-08
CA3139512A1 (fr) 2020-11-12
CN114402079A (zh) 2022-04-26
EP3966338A1 (fr) 2022-03-16
WO2020227481A1 (fr) 2020-11-12

Similar Documents

Publication Publication Date Title
DE102020112518B8 (de) Toner
UA42395S (uk) Футляр
EP3818843A4 (fr) Cigarette
EP3818842A4 (fr) Cigarette
EP3555124C0 (fr) Tcr nyeso
EP3818840A4 (fr) Cigarette
EP3845661A4 (fr) Pyrrolysyl-arnt synthétase
EP3966249A4 (fr) Immunothérapies ciblant cll -1
DE112019006314A5 (de) Förderanordnung
JP1643514S (ja) 電子タバコ用カートリッジ
EP3745904C0 (fr) Poignée de bâton
EP3899155A4 (fr) Raccord amélioré
EP3904110A4 (fr) Cartouche
JP1643249S (ja) 電子タバコ用カートリッジ
EP3721129A4 (fr) Cryosphère
PL3829776T3 (pl) Komora flotacyjna
DE112019006342A5 (de) Förderanordnung
EP3904107A4 (fr) Cartouche
JP1650005S (ja) 電子タバコ用カートリッジ
EP3975763B1 (fr) Cigarillo
DK3752258T3 (da) Trampolin
PL3829774T3 (pl) Komora flotacyjna
PL3880011T3 (pl) Sposób
EP3773733C0 (fr) Métallo-liothyronine
DK3711623T3 (da) Kuffert